Targeting trypanosomatid deoxyhypusine synthase
靶向锥虫脱氧马匹氨酸合酶
基本信息
- 批准号:9813821
- 负责人:
- 金额:$ 47.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-12-15 至 2021-11-30
- 项目状态:已结题
- 来源:
- 关键词:Active SitesAfrican TrypanosomiasisAmino AcidsBasic Amino AcidsBiochemicalBiological AssayBiological ProcessBrainCellsCellular AssayChagas DiseaseChemicalsDiseaseDrug KineticsDrug TargetingEntamoebaEnzymesEukaryotaEukaryotic CellEukaryotic Initiation FactorsEvaluationGenetic TranslationGoalsGrowthHumanHuman Cell LineImpairmentIn VitroInfectionLeadLeishmaniaLeishmaniasisLibrariesLinkLysineMass Spectrum AnalysisMetabolismModelingModificationMusParasitesPathogenicityPenetrationPermeabilityPharmaceutical ChemistryPharmaceutical PreparationsPharmacotherapyPhasePolyaminesPropertySeriesSolubilitySpermidineStructureTestingToxic effectTrypanosoma brucei bruceiTrypanosoma cruziValidationbasecell growthcell killingcombatcytotoxicitydeoxyhypusine synthasegene producthigh throughput screeninghypusinein vitro Assayin vivoin vivo evaluationinhibitor/antagonistlead optimizationmeetingsmouse modelneglected tropical diseasesnovelnovel strategiesparalogous genepre-clinicalprogramsresistance mechanismscreening programsmall moleculesmall molecule inhibitortranslation factortreatment program
项目摘要
Project Description.
Trypanosomatid parasites are the causative agents of human African trypanosomiasis (HAT),
Leishmaniasis and Chagas disease, all of which are listed by the WHO as Neglected tropical diseases
(NTDs). Collectively 18-20 million people are infected with one of these parasites, yet drug therapies
remain inadequate for all three diseases. Discovery of a drug-target that could be exploited against all
three parasites, while not showing toxicity against the host, would provide a robust new approach to
combat these diseases. Eukaryotes universally require a translation factor called eIF5A for cell growth.
To be active eIF5A must be post-translationally modified on a conserved lysine reside to generate a
novel amino acid called hypusine. The hypusine modification of eIF5A is catalyzed by deoxyhypusine
synthase (DHS) using spermidine as a substrate. DHS is an essential enzyme in all eukaryotes including
the trypanosomatids. We previously demonstrated that DHS from trypanosomatids and Entamoeba have
uniquely evolved to require heterotetramer formation between two paralogous gene products to generate
the active enzyme. This unusual configuration of these parasite DHSs suggests that it may be feasible to
identify selective inhibitors of the parasite enzymes that don't inhibit human DHS. The goal of this
proposal is to determine if drug-like inhibitors of DHS that are selective for the trypanosomatid enzymes
can be identified and if so to advance them during a lead optimization program for the treatment of HAT.
In the R21 phase of this proposal we plan to develop a high throughput screen (HTS) compatible assay
for T. brucei DHS and to use this assay to screen the UT Southwestern 200,000 compound library for T.
brucei DHS inhibitors. We will perform hit validation on identified inhibitors and determine if the
identified inhibitors show good selectivity versus human DHS. If trypanosomatid specific DHS
inhibitors with good drug like properties can be identified than in the R33 phase of the proposal we plan
a hit to lead optimization of at least one series with appropriate properties to be advanced for the
treatment of HAT. Identified DHS inhibitors will also be tested at various stages during hit validation
and lead optimization against T. cruzi and Leishmania to determine if they have the potential to be
developed as a broad-spectrum treatment for all three trypanosomatid-based diseases.
项目描述。
锥虫寄生虫是人类非洲锥虫病(HAT)的病原体,
利什曼病和恰加斯病,均被世界卫生组织列为被忽视的热带病
(NTD)。总共有1800万至2000万人感染了这些寄生虫之一,但药物治疗
对所有三种疾病来说都是不够的。发现了一种可以用来对付所有人的药物靶点
三种寄生虫,虽然没有显示出对宿主的毒性,但将提供一种强大的新方法,
对抗这些疾病。真核生物普遍需要一种称为eIF5A的翻译因子来进行细胞生长。
为了具有活性,eIF5A必须在保守的赖氨酸残基上进行后修饰,以产生一种新的活性。
一种叫做羟腐胺赖氨酸的新氨基酸eIF5A的羟腐胺赖氨酸修饰由脱氧羟腐胺赖氨酸催化
合成酶(DHS),使用亚精胺作为底物。DHS是所有真核生物中的必需酶,包括
锥虫我们以前证明,从锥虫和内阿米巴DHS有
独特地进化到需要在两个旁系同源基因产物之间形成异源四聚体以产生
活性酶。这些寄生虫DHS的这种不寻常的配置表明,
确定寄生虫酶的选择性抑制剂,这些酶不抑制人类DHS。这个目标
建议是确定是否有选择性的锥虫酶的DHS药物样抑制剂
如果是,则在用于治疗HAT的导联优化程序期间推进它们。
在该提案的R21阶段,我们计划开发一种高通量筛选(HTS)兼容的检测方法
对于T.布氏锥虫DHS,并使用该测定筛选UT西南200,000化合物库中的T.
布鲁氏菌DHS抑制剂。我们将对识别出的抑制剂进行命中验证,并确定
鉴定的抑制剂显示出对人DHS的良好选择性。如果锥虫特异性DHS
与我们计划的R33阶段相比,可以确定具有良好药物样特性的抑制剂
一个命中,以导致优化至少一个系列与适当的属性,以提前为
HAT的治疗已确定的DHS抑制剂也将在命中验证期间的各个阶段进行测试
并针对T. cruzi和利什曼原虫,以确定它们是否有潜力成为
作为所有三种锥虫疾病的广谱治疗方法而开发。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Margaret A. Phillips其他文献
Role of the prodomain in folding and secretion of rat pancreatic carboxypeptidase A1.
前结构域在大鼠胰腺羧肽酶 A1 折叠和分泌中的作用。
- DOI:
- 发表时间:
1996 - 期刊:
- 影响因子:2.9
- 作者:
Margaret A. Phillips;William J. Rutter - 通讯作者:
William J. Rutter
Cloning and sequencing of the ornithine decarboxylase gene from Trypanosoma brucei. Implications for enzyme turnover and selective difluoromethylornithine inhibition.
布氏锥虫鸟氨酸脱羧酶基因的克隆和测序。
- DOI:
- 发表时间:
1987 - 期刊:
- 影响因子:4.8
- 作者:
Margaret A. Phillips;P. Coffino;Chao Wang - 通讯作者:
Chao Wang
Margaret A. Phillips的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Margaret A. Phillips', 18)}}的其他基金
Optimization of novel phenotypic screening hits for treatment of Malaria
用于治疗疟疾的新型表型筛选靶标的优化
- 批准号:
10652726 - 财政年份:2021
- 资助金额:
$ 47.45万 - 项目类别:
Optimization of novel phenotypic screening hits for treatment of Malaria
用于治疗疟疾的新型表型筛选靶标的优化
- 批准号:
10376179 - 财政年份:2021
- 资助金额:
$ 47.45万 - 项目类别:
Optimization of novel phenotypic screening hits for treatment of Malaria
用于治疗疟疾的新型表型筛选靶标的优化
- 批准号:
10594538 - 财政年份:2021
- 资助金额:
$ 47.45万 - 项目类别:
Optimization of novel phenotypic screening hits for treatment of Malaria
用于治疗疟疾的新型表型筛选靶标的优化
- 批准号:
10721415 - 财政年份:2021
- 资助金额:
$ 47.45万 - 项目类别:
Lead optimization of DHODH inhibitors for malaria
疟疾 DHODH 抑制剂的先导优化
- 批准号:
8601042 - 财政年份:2013
- 资助金额:
$ 47.45万 - 项目类别:
Lead Optimization of DHODH Inhibitors for Malaria
疟疾 DHODH 抑制剂的先导优化
- 批准号:
10736209 - 财政年份:2013
- 资助金额:
$ 47.45万 - 项目类别:
Lead optimization of DHODH inhibitors for malaria
疟疾 DHODH 抑制剂的先导优化
- 批准号:
8440181 - 财政年份:2013
- 资助金额:
$ 47.45万 - 项目类别:
Lead optimization of DHODH inhibitors for malaria
疟疾 DHODH 抑制剂的先导优化
- 批准号:
8975598 - 财政年份:2013
- 资助金额:
$ 47.45万 - 项目类别:
Lead optimization of DHODH inhibitors for malaria
疟疾 DHODH 抑制剂的先导优化
- 批准号:
8776264 - 财政年份:2013
- 资助金额:
$ 47.45万 - 项目类别:
相似海外基金
The catalytic core of the proteasome as a drug target to treat Human African Trypanosomiasis
蛋白酶体的催化核心作为治疗非洲人类锥虫病的药物靶点
- 批准号:
10511408 - 财政年份:2022
- 资助金额:
$ 47.45万 - 项目类别:
A One Health approach to investigating the ecology of East African trypanosomiasis in Malawian wildlife
调查马拉维野生动物中东非锥虫病生态学的“同一个健康”方法
- 批准号:
476178 - 财政年份:2022
- 资助金额:
$ 47.45万 - 项目类别:
Studentship Programs
The catalytic core of the proteasome as a drug target to treat Human African Trypanosomiasis
蛋白酶体的催化核心作为治疗非洲人类锥虫病的药物靶点
- 批准号:
10677879 - 财政年份:2022
- 资助金额:
$ 47.45万 - 项目类别:
Multi-target approach to rational design of novel therapeutics for human African trypanosomiasis
多目标方法合理设计非洲人类锥虫病新疗法
- 批准号:
10466942 - 财政年份:2021
- 资助金额:
$ 47.45万 - 项目类别:
Multi-target approach to rational design of novel therapeutics for human African trypanosomiasis
多目标方法合理设计非洲人类锥虫病新疗法
- 批准号:
10296873 - 财政年份:2021
- 资助金额:
$ 47.45万 - 项目类别:
Multi-target approach to rational design of novel therapeutics for human African trypanosomiasis
多目标方法合理设计非洲人类锥虫病新疗法
- 批准号:
10706306 - 财政年份:2021
- 资助金额:
$ 47.45万 - 项目类别:
Reducing and replacing the animal cost of functional genetics in African trypanosomiasis
减少和替代非洲锥虫病功能遗传学的动物成本
- 批准号:
NC/W001144/1 - 财政年份:2021
- 资助金额:
$ 47.45万 - 项目类别:
Research Grant
Development of new drug for African trypanosomiasis based on elucidation of the mechanism of antiprotozoal action by ribavirin.
基于利巴韦林抗原虫作用机制的阐明,开发治疗非洲锥虫病的新药。
- 批准号:
21K18230 - 财政年份:2021
- 资助金额:
$ 47.45万 - 项目类别:
Grant-in-Aid for Challenging Research (Pioneering)
Development of a novel control measure for African trypanosomiasis based on the blocking of lifecycle progression
基于生命周期进展阻断的非洲锥虫病新型控制措施的开发
- 批准号:
20K07467 - 财政年份:2020
- 资助金额:
$ 47.45万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Drug-diagnostic co-development in Tropical Medicine, combating Human African Trypanosomiasis
热带医学药物诊断联合开发,抗击非洲人类锥虫病
- 批准号:
18KK0454 - 财政年份:2019
- 资助金额:
$ 47.45万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))